Chimi Laetitia Fosso, MD
Hematology & Oncology · Sugar Land, TXNPI 1285029579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $784, more than ten times the $21 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 42 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$91
- E.r. Squibb & Sons, L.L.C.$81
- Eisai Inc.$67
- Regeneron Healthcare Solutions, Inc.$58
- Lilly USA, LLC$56
- AstraZeneca$55
- plus $596 from 19 others
What the payments were for
- Food & beverage$1,004100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Eisai Inc. | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| Lilly USA, LLC | 2 | $56 |
| AstraZeneca | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Sobi, Inc | 2 | $51 |
| ADC Therapeutics America, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Sanofi | 1 | $35 |
| Taiho Oncology, Inc. | 1 | $32 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Novartis | 1 | $29 |
| Bayer | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Pfizer | 1 | $25 |
| AbbVie | 1 | $22 |
| Morphosys, US Inc. | 1 | $22 |
| Seagen Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| GSK | 1 | $17 |
How this compares
$1,004 in reported general payments places this provider in the 30th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Sugar Land
- Jorge DarcourtSugar Land$132K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.